Jun Bao, PhD, MBA
Senior VP & Chief Business Officer, Shenogen Pharma Group

Dr. Jun Bao is Senior Vice President and Chief Business Officer. He has over 20 years of combined business and science experiences. Before he joined Shenogen, Jun was Director, Worldwide Business Development, Head of China at GlaxoSmithKline (GSK). Prior to GSK, he worked at Onyx Pharmaceuticals, ICOS Corporation and Cell Therapeutics as a business development executive with progressive responsibilities. Jun also worked as a finance manager in Procter & Gamble based in Cincinnati. Jun received a BS in Microbiology from Shandong University and a PhD in Neuroscience from University of Kansas. He completed his postdoctoral fellowship in Johns Hopkins University. In addition, he received an MBA in Finance from University of Chicago. He has authored/co-authored more than 30 research publications and co-founded two start-up biotech companies.

Xue Bin
Deputy Director General, CCPIE

Leon Chen
Lian Yong (Leon) Chen, PhD, Founder & Managing Partner, Frontline BioVentures

Dr. Chen is Founder and Managing Partner of Frontline BioVentures. He has over eighteen years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor. He is a member of the Expert Review Panel for the Chinese Central Government HR’s 1,000 Talent Project, and an adviser to BioBAY of Suzhou Industry Park. As a venture capital investor, his current and past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Director of Board, Acting CFO), Cathay Industrial Biotechnology (Director of Board), Hile Biopharma (Director of Board), Hua Medicine (Shanghai) (Director of Board), Innovent Biologics Ltd (Chairman), Adagene (Director of Board) and MDDF (Director of Board). As a management consultant, his past affiliations include McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area). 

During his 18 year pharma career, Dr. Chen also had several leadership positions at Roche Nutley in New Jersey, including Head of high throughput chemistry and project leadership in metabolic diseases and cancer. He is a co-inventor of two Roche drugs that have completed Phase II clinical trials in Asthma and in MED. He also served as a member at Roche’s Patent Coordination Committee at Nutley.

Dr. Chen was the President of the Sino-American Pharmaceutical Professionals Association (SAPA) in 2001, and is now a member of the SAPA Board of Directors.

Li Chen, Ph.D.
President & CEO, Hua Medicine, China

Dr. Li Chen is the co-founder and CEO of a newly established drug discovery and development company, Hua Medicine, which brings clinically differentiated medicine to the patients in China and rest of world. Before Dr. Chen founded Hua Medicine, he was the Chief Scientific Officer and Head of Research at Roche R&D Center (China) Ltd. and a member of Roche Pharma Research Leadership Team. As a founding Director in this position, Li was responsible for development and implementation of China drug discovery strategy, creation of China discovery portfolio, and management of China operation, including Biology, Chemistry, Pharmacology, Discovery Technology, Drug Supply and Drug Safety.  

Li received his Ph.D in Chemistry from Iowa State University. He was formerly a lecturer in Organic Chemistry at East China Normal University, and is currently an adjunct professor of Chemical Biology at Tongji University. He has over 70 publications in numerous peer-reviewed scientific journals and in patent literature.

Shaoyu Chen, Ph.D.
Partner, Covington & Burling LLP

Mr. Shaoyu Chen is a partner in the firm’s Food and Drug Practice Group, and the managing director of its China Food and Drug Practice, based in the firm’s Beijing and Shanghai offices. Mr. Chen has over a decade of experience in food and drug law, including serving in the government, and the biopharmaceutical and medical device industries  

Leveraging these hands-on government and industry experiences, Mr. Chen effectively assists multinational and Chinese pharmaceutical, biotechnology, medical device, food, and cosmetic companies and trade associations to address the most pressing regulatory law issues confronting business.

Mr. Chen has the privilege to represent industry leaders such as Abbott, Amgen, AstraZeneca, BMS, Genentech, Gilead Sciences, Merck, Novartis, Stryker, Takeda, and UBC, as well as many start-up or mid-size firms on a full range of matters regulated by the U.S. FDA and China FDA (CFDA, formerly SFDA).

Samantha Du
Managing Director, Sequoia Capital China

Samantha Du, Managing Director of Sequoia Capital China, focuses on healthcare investment. Prior to joining Sequoia in 2012, Dr. Du was the founder and CEO of Hutchison MediPharma Limited since 2001. She also co-founded Hutchison China MediTech Limited, where she acted as its CSO and played a key role in its sucessful IPO on UK Aim market. Before Hutchison MediPharma, Dr. Du worked at Pfizer US, where she was responsible foe global metabolic diseases licensing on the scientific side.

Samantha started her industry career at Pfizer US global R&D headquarter, where she led teams involved in drug development in various stages and therapeutic areas, two of the products she worked on had received global regulatory approval and launch. Dr. Du received her Ph.D. in Biochemistry from University of Cincinnati. She is currently an adjunt professor at Fudan University and chairwoman of shanghai pudong drug innovation consortium. She is an recipient both of thousand talent program in shanghai and of shanghai Magnolia award. She is on the board of BGI tech, JHL biotech, Beta Pharma.

May-Kin Ho, PhD
Advisory Director, Goldman, Sachs & Co.

Dr. Ho is an advisory director to the firm. Previously, she was a biotechnology analyst and co-head of US Healthcare for Global Investment Research. She joined Goldman Sachs in 1992 and was named managing director in 1998 and partner in 2002.

Dr. Ho has been ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for over 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times.

Prior to joining the firm, she held senior management positions in research, marketing and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company.

Dr. Ho serves on the board of The Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University and the Investment Committee of the Society for Neuroscience. She has also served on the Biological Chemistry Advisory Council at Harvard Medical School.

Dr. Ho was a postdoctoral fellow at Harvard Medical School. She earned a PhD in Microbiology and Immunology from the State University of New York, Downstate Medical Center.

Kewen Jin
Managing Director, Nimbus Innoworks

Mr. Kewen Jin is a serial entrepreneur in China life science industry. He is currently Managing Director of Nimbus Innoworks, a life science incubator based in Suzhou. He was previously General Manager of Charles River Lab’s China company. Kewen has co-founded and served as CEO of several companies in CRO biotech and medical device.

He is an advisor to Suzhou Biobay, a leading life science park in China. He served as advisor to several multinational pharmaceutical companies, investment and consulting firms and NGOs. He was a marketing and international operation executive with Wyeth from 1993 to 2000 , in the U.S. and in China.

He was trained in medicine (Shanghai Jiaotong University), molecular biology (Rockefeller), and finance (Columbia). He was granted the 2005 Magnolia Award by the Shanghai government. He served as the founding Chair of the Shanghai CRO Association. He was a Board member for Bayhelix.

James Li
Vice President & General Manger, Greater China, Amgen China

Dr. James Li is the Vice President and General Manager, Amgen China where he is leading the company’s efforts in expanding business into the Chinese market and helping Chinese patients to access Amgen’s vital medicines.

Prior to joining Amgen, Dr,. Li was a Partner at Kleiner Perkins Caufield & Byers’ life sciences practice, first in the US Pandemic Fund and later, in its China Fund. He successfully invested in a number of early stage and growth stage companies, and led a portfolio company that went to public in 2010.

From 1991 to 2006, Dr. Li spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across the Asia Pacific Region when the Vaccine Division started operations in the region; he also successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s largest franchise in Asia.

Dr. Li received his Medical Degree from Shanghai Medical University, followed by a Master of Science degree in Microbiology from the University of Montana.

Bo Liu, PhD
Principal, Venture Investments
Johnson & Johnson Development Corporation

Bo Liu, PhD, Principal, Venture Investments, joined Johnson & Johnson Development Corporation in January 2013. He is based in Shanghai, China.

Most recently Dr. Liu was Director of Business Development and Strategic Planning with GlaxoSmithKline Consumer Healthcare China, where he led key strategic initiatives in mergers and acquisitions, licensing and portfolio optimization. Prior to joining GSK, he worked in the corporate development and strategy group with Charles River Laboratories in Boston, where he played an instrumental role in several strategic transactions. Dr. Liu has executed M&A and licensing transactions in the US, Europe and Asia (including China) with total considerations over $2 billion.

Dr. Liu received a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago, and a Master of Medicine from the seven-year program of Tongji Medical University in Wuhan, China. He received residency training in Urology at Union Hospital of Tongji Medical University.

John Oyler
Founder & CEO, BeiGene

John Oyler was the former Founder & CEO of BioDuro, a 700-person integrated research CRO in Beijing and former CEO of Galenea (Boston biotech started from MIT with funding from Otsuka).

He was the former co-CEO of Genta (GNTA), a publically traded oncology company that subsequently grew in the late 1990s to $1.7B. He was also the former Founder and President of Telephia (bought by Nielsen). He received his MBA from Stanford, and his BS from the Massachusetts Institute of Technology.

Yinxiang Wang, Ph.D.
CEO and Chief Scientific Officer, Zhejiang Beta Pharma

Dr. Yinxiang Wang is the CEO and Chief Scientist of Zhejiang Beta Pharma, Inc. He is a member of the Chinese Program of Global Experts (also known as the “1000 Plan”).In his current position, Dr. Wang, is instrumental in the research and development of a great number of new drugs for oncology and diabetes.

As the Chief Scientist and one of the main innovators at Zhejiang Beta Pharma, Dr. Wang headed the research team which developed and commercialized Icotinib Hydrochloride (Conmana®), a National Category 1 Novel Drug that is the first small molecule oncology drug specifically targeting cancer cells that is completely developed in China.  Zhejiang Beta Pharma successfully obtained approval on Icotinib Hydrochloride from Center for Drug Evaluation at SFDA at the end of 2010 and started marketing Conmana® in 2011.

Dr. Wang is also one of the founders of Zhejiang Beta Pharma New Drug Research Center in Beijing, established in 2003. Currently, he is leading the scientists at the center in researching and developing pipeline drugs that include eight Category 1 drugs and several Category 3 drugs, out of which five generic products have already been approved and commercialized. In 2011, Eli Lilly invested in and formed a strategic 27 alliance with Zhejiang Beta Pharma that marked the beginning of new collaboration efforts to develop future products and technologies.

Jerry Xiao
Vice General Manager, Corporate Technology Center, Fosun Pharma

Dr. Xiao received his Ph.D. in Pharmacology from The Second Military Medical University. While in his postdoctoral training at the University of Rochester, he founded a small pharmaceutical company in the U.S.

Before joining FosunPharma in June 2008, he was an investment manager at a VC company. Currently, he is responsible for identifying, evaluating, and developing new product and technology opportunities from the whole globe, as well as directing FosunPharma Group’s investments to R&D companies.

He has invested in two R&D companies and in-licensed three projects for FosunPharma. He is also a member of the Board of Directors of Fochon Pharma and Henlius Biotech

Steve Yang
Vice President, Head of R&D, Asia and Emerging Markets, AstraZeneca, China

Dr. Steve Yang is Vice President, Head of R&D for Asia and Emerging Markets at AstraZeneca. He is based in Shanghai, China and is responsible for developing, implementing and aligning the company’s R&D strategy for Asia and Emerging Markets.

Prior to joining AstraZeneca, Dr. Yang was Vice President, Head of Asia R&D at Pfizer, where he was charged with establishing and expanding the company’s research partnership network with academic institutions, biotechnology firms and Contract Research Organizations across Asia Pacific. He was also responsible for delivering a portfolio of preclinical and clinical stage projects targeting unmet medical needs of emerging markets. Prior to his leadership position in Asia, Dr. Yang was Executive Director and head of the company’s global R&D strategic management group.

Before joining Pfizer Dr. Yang held a number of positions at IntraBiotics Pharmaceuticals, a US-based biotech company and also worked for Strategic Decisions Group (SDG), a management consulting firm for Fortune 100 companies.

Dr. Yang is the co-founder of the BayHelix Group, a non-profit professional organization of Chinese life science business leaders.

Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, USA. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude in Biology from Michigan Technological University, USA.

Jimmy Zhang, PhD, MBA
Managing Director, MSD Early Investments Greater China, Merck & Co., Inc.

Dr. Jimmy Zhang is the Managing Director, MSD Early Investments – Greater China at Merck & Co. He's responsible for Merck's venture capital investments, licensing, acquisitions, external research collaboration, and alliance/partnership management in Greater China.

Before joining Merck/MSD, Jimmy was a Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Synergenics invests and manages early-stage companies in drug discovery, vaccine, diagnostics, and healthcare IT. Jimmy is responsible for the business development and operations of Synergenics and some of its portfolio companies, and their businesses in China. Jimmy was previously a consultant at McKinsey & Company, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis).

Jimmy received his B.S. in biochemistry from Nanjing University, and Ph.D. in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with two Nobel Laureates. While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council. He was also a finalist of the 12th Annual MIT $50K Entrepreneurship Competition.

Jimmy is a founding member and the current Chairman, Board of Directors of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. Jimmy is also the Strategic Advisor to both ChinaSF and China Committee of Bay Area Council, and a guest/adjunct professor at Tongji University, Shanghai.

Xun Zhu, MD
Professor, Department of Immunology, Jilin University

Sun Xianzue
Deputy Commissioner, State Food and Drug Administration (SFDA)

Sun Xianze has been serving as Deputy Commissioner of the SFDA since September 2012.

VC Sun has a long a prestigious career with the SFDA, serving as the Director of the Information Center of the Drug Supervision Management Bureau prior to being appointed VC of the SFDA. Before that, he served as the Director General of the Department for Drug Supervision (2009 – 2011) and the DG of the Department of Food Safety Supervision (2008 – 2009), and DG of the Food Safety Coordination Department (2003 – 2008).

Prior to joining the SFDA, Sun served with the Sichuan Provincial Food and Drug Administration from 1991 to 2000, being appointed as the Deputy Bureau Chief in May 2000. He held that position until being promoted to the SFDA in 2003.

Born in Jiangsu Province in June 1957, Sun graduated with a bachelor’s degree from China Pharmaceutical University in Nanjing, Jiangsu Province in 1982.

Governor Jon M.  Huntsman Jr.

Jon Huntsman served as Ambassador to China from 2009 thru April, 2011 when he stepped down to run for the 2012 Republican nomination for President. Prior to serving as Ambassador to China, Huntsman was twice elected as Governor of Utah, including in 2008 with a record percent of the vote, including the majority in all 29 counties. As Governor, Huntsman governed with his eye toward maintaining Utah’s unparalleled quality of life, continually increasing the state’s economic competitiveness and maximizing funding to Utah’s public education system.

Huntsman’s breadth of experience in Asia has been developed over a lifetime of interest and involvement. He has previously lived in Asia four times and speaks fluent Mandarin Chinese.

Huntsman’s public service career began as a White House staff assistant to President Ronald Reagan and has since included appointments as Deputy Assistant Secretary of Commerce for Asia, U.S. Ambassador to Singapore and Deputy U.S. Trade Representative. As a U.S. Trade Ambassador, Huntsman negotiated dozens of free trade agreements, trade and investment framework agreements and brokered other bi-lateral and multi-lateral trade agreements for the United States with China, Taiwan, Singapore, Australia, India, Vietnam, West Africa, South Africa and other Asian and African nations. He played a critical role in launching global trade negotiations in Doha, Qatar in November of 2001, guiding the simultaneous accession of China and Taiwan into theWorld Trade Organization.

He is a founding director of the Pacific Council on International Policy and has served on various boards such as the Brookings Institute Asia Policy Board, the Center for Strategic and International Studies Pacific Forum, the Asia Society in New York and the National Bureau of Asian Research.

During his tenure as Governor, Utah was repeatedly recognized by many prestigious organizations for its dynamism, business climate and quality of life. Perhaps most importantly, Utah was named by the Pew Center as the Best Managed State in America. Even in times of economic hardship, Huntsman worked collaboratively with stakeholders to minimize impacts to critical human services while maintaining job-stimulating construction projects and keeping the State's Rainy Day Fund intact as a tool for any future fiscal distress.

Recognized nationally for his leadership, Huntsman served as chairman of the Western Governors Association and on the Executive Committee of the National Governors Association.

As a dedicated public servant, Huntsman is committed to serving in this critical post as Ambassador to one of the most important international relationships for the United States of America. He is a graduate of the University of Pennsylvania and has four honorary doctorate degrees.

Huntsman and his wife, Mary Kaye, live in Washington DC. They have seven children.

Perry Karsen
EVP, Chief Operations Officer, Celgene Corporation

Perry Karsen is an Executive Vice President  and currently serves as Chief Operations Officer at Celgene Corporation. Mr. Karsen served as President and Chief Executive Officer at Pearl Therapeutics, a privately-held biotechnology company, from February 2009 until July 2010. Previously,  Mr. Karsen was Senior Vice President and Head of Worldwide Business Development at Celgene and was also responsible for emerging businesses as President, Asia/Pacific Region. Perry served as  Senior Vice President, Business Development at Human Genome Sciences; and earlier in his career, held positions including Vice President, Strategic Business Analysis and Development, Bristol-Myers Squibb; Senior Vice President Marketing and Sales, Zimmer, Inc.; Director, Business Development and Representative Director, Japan, at Genentech; and various domestic and international roles with Abbott Laboratories. Additionally, Mr. Karsen was a General Partner at Pequot Ventures responsible for early and late stage investments in biotechnology and medical devices.

Mr. Karsen serves as a member of the Board of Directors of the Biotechnology Industry Organization (BIO), the world’s largest biotechnology industry organization; a member of the Board of Directors of BayBio, representing the biotechnology industry in the San Francisco Bay Area; and a member of the Board of Directors for the Life Sciences Foundation, an organization dedicated to telling the story of biotechnology.  In addition, Mr. Karsen is a member of the Board of Directors of Agios Pharmaceuticals, a private biotechnology company pioneering research in cancer metabolism.

Mr. Karsen has a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a BS in Biological Sciences from the University of Illinois, Urbana.

Peng Wang, Ph.D.
Chief Scientific Officer, Simcere

Dr. Peng Wang, a member of the China National “1000-Talents Program”, is currently Chief Scientific Officer of Simcere Pharmaceuticals Group, a leading Chinese pharmaceutical company headquartered in Nanjing, China (simcere.com; “SCR” at NYSE). Prior to joining Simcere, Dr. Wang was with WuXi PharmaTech (wuxiapptec.com; “WX” at NYSE), a leading pharmaceutical CRO in China, as Vice President of Discovery Biology in 2008-2009. Prior to joining WuXi PharmaTech, Dr. Wang worked on discovery through early clinical development for Schering-Plough in New Jersey, USA for 18 years. Dr. Wang has made significant contributions to discovery and early development of 16 drug candidates in US and China, and to establishment of several collaboration partnerships between Simcere and US companies. Dr. Wang has published numerous papers as corresponding author in leading scientific journals such as Proc. Natl. Acad. Sci. USA, J. Biol. Chem., Blood, J. Immunol., Am. J. Respir. Crit. Care Med., Mol. Pharmacol., Biochem. J. etc. Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo, and his B.S. in Medicinal Chemistry from the China Pharmaceutical University.

Michael Rosenblatt, M.D.
Executive Vice President and Chief Medical Officer, Merck (MSD)

Scientist, educator, hospital and global healthcare company executive, Michael Rosenblatt, M.D., is executive vice president and chief medical officer at Merck. He is the company’s primary external advocate on medical issues and represents the voice of the patient inside Merck.

Dr. Rosenblatt previously was Dean of Tufts University School of Medicine; the George R. Minot Professor of Medicine at Harvard Medical School; and president of Beth Israel Deaconess Medical Center (BIDMC). He was the Harvard faculty dean and senior vice president for academic programs at BIDMC. He was also director of the Harvard-MIT Division of Health Sciences and Technology.

Prior to these leadership positions, he was senior vice president for research at Merck where he co-led the worldwide development team for alendronate (FOSAMAX®). Earlier, he was chief of the Endocrine Unit at the Massachusetts General Hospital.

Committed to innovation, he has served on the board of directors and scientific advisory boards of several biotechnology companies and is a scientific founder of ProScript, Radius Pharmaceuticals and Theracrine.

Dr. Rosenblatt was elected to the American Society of Clinical Investigation and the Association of American Physicians, is a fellow of the American Association for the Advancement of
Science and the American College of Physicians, and served as the president of the American Society of Bone and Mineral Research.

He received his undergraduate degree summa cum laude from Columbia University and his M.D. magna cum laude from Harvard Medical School.

Zhao Yajun
Director General, China Center for Pharmaceutical International Exchanges (CCPIE), State Food and Drug Administration (SFDA)

Mr. Zhao Yajun has been the DG of CCPIE since 2002, and prior to that Mr. Zhao Yajun was the Division Director of the International Cooperation Department of State Food and Drug Administration.

For a long time, Mr. Zhao Yajun has worked in international cooperation and has a lot experiences in international regulatory exchange.

Xu Zuxin
Deputy Director General, Science and Technology Commission of Shanghai Municipality

Ms. Xu Zuxin, currently the Deputy Director of the Science and Technology Commission of Shanghai Municipality (STCSM), has taken the position since September, 2007. She is now in charge of the Division of International Cooperation and Division of Bio-medicine, and assists administration of the Division of Basic Research.

Before that, Ms. Xu has successively served as the assistant to the President of Tongji University, executive deputy director for the leading group of environmental remediation and recovery for the Suzhou River in Shanghai, as well as the deputy director general and director general of the Shanghai Environmental Protection Bureau. Ms. Xu was born in Pingxiang, Jiangxi province.

Registration Type

Early
Registration Fee

Registration Fee
After Deadline

BIO Member

$1,295

$1,495

Non-Member

$1,595

$1,895

Academic

$650

$650

Investor 

$650

$650

Sam Liao -  Sam Liao is the Asia Head of Business Development & Licensing for Novartis Vaccines & Diagnostics, Inc. He is responsible for the evaluation, negotiation, and execution of various commercial, licensing and co-development deals with international biotech companies and academics. He is also responsible for merger and acquisition activities and manages business alliances in Asia Pacific region.

Before joining Novartis, he was a Director of Corporate Development at Sanofi Pasteur, where he has over 15 years’ experiences working in the vaccine industry and held various positions in R&D, Marketing, Project Management and Strategic Planning. He has executed multiple deals worth more than $1 billion, and signed agreements with companies in North America, Europe, Japan and Australia. He was responsible for several high-profile government contracts with HHS, CDC and NIH, for SARS vaccine and pandemic avian influenza vaccine developments.

Sam Liao earned his medical degree from West China University of Medical Sciences, a Master’s degree on Biochemistry from University of Scranton, and an MBA from Columbia University. 

James McGregor - Mr. McGregor is a senior counselor for APCO Worldwide in China, author of the bestselling book One Billion Customers: Lessons from the Front Lines of Doing Business in China and a veteran reporter for The Wall Street Journal. Prior to joining APCO, he served as chairman and CEO of a China-focused consulting and research firm for hedge funds. He also held previous roles as a senior advisor for Ogilvy Public Relations China and the China managing partner for GIV Venture Partners, a venture capital fund that focused on technology and Internet investments in China and India.

Mr. McGregor was a reporter in the Washington bureau of Knight-Ridder newspapers during the Reagan administration. After serving as the Taiwan bureau chief for The Wall Street Journal from 1987 to 1990 and China bureau chief from 1990 to 1994, he spent seven years building Dow Jones’ media business in China as CEO of Dow Jones’ China operations and an international vice president of the company. During this time, he established CNBC in China and created the Chinese language Web site of wsj.com, Dow Jones’ Chinese-language newswires, Chinese stock-market indexes and the first weekly business-television show in China. He was also a Series A investor in Sohu.com and served on their board for several years, including during the company’s NASDAQ listing. After successfully preventing Xinhua News Agency from obtaining a monopoly on financial information in China, he received the Barney Kilgore award, Dow Jones’ highest employee accolade.

Mr. McGregor is a professional speaker, regular television and radio commentator and a contributor of essays and opinion articles for a variety of publications. He has more than 20 years of China experience and can speak and read Chinese. He was an active member of the Board of Governors of the American Chamber of Commerce in China (AmCham) for more than 10 years and served as chairman in 1996. He is currently chairman of the U.S. Government Relations Committee for AmCham. He is also a member of the Council on Foreign Relations, a Global Council member of the Asia Society, a board member of the U.S.-China Education Trust and a member of the National Committee on U.S.-China Relations.

Michel Vounastos - With nearly 20 years experience in healthcare industry, Mr. Vounatsos brings a vast knowledge and expertise to drive MSD China to the new levels of success.

Mr. Michel Vounatsos has extensive experience across the world, Europe (France, Belgium, Poland) but also in the US, Middle-East and Africa. His last assignment before coming to China was the president of MSD in France, one of the largest MSD subsidiaries outside the US. During his assignment as the Managing Director of MSD Poland, he was able to significantly increase MSD's presence while supporting the Health Care reform of this emerging market. Due to his profound experience in mature and emerging markets, his appointment demonstrates China's strategic significance to MSD as well as the company's continuous investment and commitment to best serve China, including providing development and career opportunity to the best talent in China.

Shaoyu Chen - Shaoyu Chen is a member of the firm’s Food and Drug practice group and the managing director of its China food and drug practice.  Mr. Chen has over 10 years experience in food and drug law, including serving as assistant chief counsel at the United States Food and Drug Administration Office of Chief Counsel, as senior counsel at Amgen Inc., and as chief compliance counsel for GE Healthcare China.  Mr. Chen represents pharmaceutical, biotechnology, medical device, food, dietary supplement, and cosmetic companies in matters before the China SFDA, the U.S. FDA, and other government agencies.  He regularly assists clients on legal and regulatory issues related to SFDA and FDA oversight, including those pertaining to preclinical research, clinical trial, marketing approval, advertising and promotion, manufacturing GMP, pharmacovigilance, import and export, and compliance with Foreign Corrupt Practices Act and China Anti-Unfair Competition Law.

John Z. Gong - Dr. Gong joined JOINN Laboratories in March 2008 with ten years of US FDA regulatory experience in new drug development. He served as a Toxicology and Pharmacology Reviewer in the FDA's Center for Drug Evaluation and Research (CDER) and conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics. These reviews covered various areas such as pharmacology, PK/PD, ADME, and toxicology studies. Since joined JOINN, Dr. Gong actively promotes and implements international standards at JOINN, leading to the AAALAC accreditation in 2008, and US FDA inspection in July 2009. JOINN’s study reports have been accepted to support clinical trials in the U.S. afterwards. Dr. Gong is a member of the Drug Safety Evaluation Committee of the Chinese Pharmaceutical Association and an ad hoc specialist of AAALAC. Dr. Gong received his Ph.D. in Toxicology from New York University in 1996 and a medical degree from Beijing Medical College in 1984.

Wassim Nashabeh, PhD - Dr Wassim Nashabeh received his Ph.D. in Analytical Chemistry from Oklahoma State University in 1993, and his post-doctoral fellowship from “Barnett Institute of Chemical and Biological Analysis” at Northeastern University where he developed new approaches for the separation of closely related recombinant protein variants. Thereafter, he joined PerSeptive Biosystems as a Senior Scientist from 1994-1996, where he co-developed new schemes for antibody modification with fluorescent and enzymatic labels for use in micro-fabricated chips based immunoassays.

In 1996, Dr Wassim Nashabeh joined Genentech (A member of the Roche Group) as a Scientist and had since held several positions of increasing responsibilities including Associate Director, Methods validation group, Director Quality Control Clinical Development, Director in the CMC Regulatory Affairs Group, Sr. Director of CMC Policy & Strategy and most recently as Global Head, Technical Regulatory Policy & Strategyfor the Roche Pharma Medicines Group. His current primary responsibilities include the development of global innovative regulatory strategies, as well as the development of key positions on a variety of subjects of significant impact to Pharma Technical Operations. Dr Nashabeh chairs the Pharma Technical External Interactions Steering Committee (PT-EISC) with responsibility for the oversight of all external outreach activities with global health authorities, industry associations and scientific organizations on technical matters.

Dr Nashabeh is the author/co-author of over 30 scientific publications, reviews and patents in the field of separation science and biotechnology. Wassim is a member of the Expert Working Group for the International Committee on Harmonization representing the BIO organization on Quality topics (currently Q11 and Q3D). Wassim is also a member of the Board of Directors of CASSS (an International Separation Science Society), co-founder and chair of the “International Symposium of CE in the pharmaceutical and Biotechnology Industries”, a permanent committee member of the CMC strategy forum conference series, co-founder of the CMC Forum Europe Conference Series as well as a member of the program committee for the WCBP conference series. Dr Nashabeh has co-chaired several biotechnology forums and events that focused on a variety of CMC related issues over the last 10 years including “Lifecycle approach of Setting Product Specifications”, “Changing paradigms for process validation”, “Design of Stability Studies”, “Quality by Design for Biotechnology Products” and “Comparability for Biotech Products”.

Nathaniel Brown - Dr. Nathaniel Brown MD is Chief Medical Officer at Presidio Pharmaceuticals, in San Francisco, CA, Previously he held positions as Chief Medical Officer at Idenix Pharmaceuticals, and for 7 years he was the Hepatitis Section head at GlaxoWellcome/GlaxoSmithKline. During his pharmaceutic career Dr Brown has led global product registration programs for AZT for children with HIV, lamivudine and telbivudine for patients with hepatitis B, lymphoblastoid interferon for hepatitis C, and atovaquone for pneumocystis pneumonia.  Dr Brown was the global leader for the lamivudine and telbivudine clinical trial programs for hepatitis B, which included prominent involvement of clinical sites in China, leveraging China’s clinical expertise in this area. For the telbivudine global registration trials, China was the lead country. China-generated clinical data were favorably reviewed by the U.S. Food and Drug Administration and by the European Medicines Agency, and played a major part in telbivudine’s successful product registrations in North America, Europe, China, and worldwide. 

During the past 20 years Dr Brown has served in various advisory roles to pharmaceutic and biotech companies, foundations, and government agencies (NIH and FDA). Prior to his pharmaceutic career Dr. Brown held full-time faculty positions in clinical infectious diseases at Cornell Medical College and U.C.L.A. School of Medicine.

Dr. Brown studied Molecular Biophysics and Biochemistry at Yale University and received his M.D. degree from Georgetown University School of Medicine. He has authored over 180 scientific publications and has received leadership awards from the Hepatitis B Foundation and the American Liver Foundation.

John Z. Gong - Dr. Gong joined JOINN Laboratories in March 2008 with ten years of US FDA regulatory experience in new drug development. He served as a Toxicology and Pharmacology Reviewer in the FDA's Center for Drug Evaluation and Research (CDER) and conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics. These reviews covered various areas such as pharmacology, PK/PD, ADME, and toxicology studies. Since joined JOINN, Dr. Gong actively promotes and implements international standards at JOINN, leading to the AAALAC accreditation in 2008, and US FDA inspection in July 2009. JOINN’s study reports have been accepted to support clinical trials in the U.S. afterwards. Dr. Gong is a member of the Drug Safety Evaluation Committee of the Chinese Pharmaceutical Association and an ad hoc specialist of AAALAC. Dr. Gong received his Ph.D. in Toxicology from New York University in 1996 and a medical degree from Beijing Medical College in 1984.

Joanne Jiang - In 2007, Dr Jiang co-founded Fountain Medical Development, a contract research organization (CRO) offering a full range of ICH GCP compliant clinical research services for multinational clients conducting clinical research in China, Hong Kong, Korea and Taiwan.  As a key contributor of the co-founding team, Dr Jiang has created an organization that is the leading regional service provider in Asia, providing clinical development solutions for global quality new drug development.

Dr Jiang has worked in the pharmaceutical industry for 14 years.  She started her career in preclinical pharmacology area at Bayer pharmaceutical and Eli Lilly, working as research scientist, lab head and project leader.  She further developed expertise in drug development and project management through her tenure as global project manager since year 2000.  From year 2000 to 2007, at Aventis and then Daiichi Sankyo, she managed drug development and life cycle management projects, encompassing phase I to phase IV clinical studies.  During her 7 years of leading clinical development teams, she has conducted global trials with study sites in US, Europe and Asia.

She especially focused on clinical trial planning and management, integrating marketing plans and regulatory strategy that enables optimal trial design, which in turn delivers best NDA filing quality and timeline.  Dr. Jiang also has working knowledge of building and managing high performing project teams that deliver break-through results. 
Dr. Jiang holds a PhD in pharmacology and toxicology from Indiana University, and an MBA from University of Michigan Dearborn.

Dr. Jiang was an Executive Council for Sino-American Pharmaceutical Association.  She is also a member of Project Management institute and Drug information association.